$LQDA

Adair Jason sold $60K of LQDA

Adair Jason (Chief Business Officer) sold 688 shares of Liquidia Corp (LQDA) at $87.53 on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Adair Jason
Published Jul 29, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 8:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosure confirms the transaction details (shares, price, date, and post-sale holdings) but does not include any new company-specific fundamental catalyst.

02

Market read

Traders may log the event for sentiment tracking, but it is unlikely to drive price action without additional corroborating news.

03

What to watch

10b5-1 plans reduce interpretability; the article does not state whether additional sales occurred under the same plan or whether the insider’s remaining holdings changed materially beyond the post-transaction figure.

Relevance 2/10Novelty 2/10Timing: SEC Form 4 filed 2026-07-29, covering a sale executed 2026-07-27.

Background

This is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by its Chief Business Officer, Adair Jason, with a stated pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia insider Adair Jason, Chief Business Officer, sold 688 shares at $87.53 on 2026-07-27 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only unless paired with other new fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, and the article contains no accompanying operational or guidance change.

Market effects

No clear sector read-through; this is a single-company insider liquidity disclosure.

None indicated.

None indicated.

Counterpoint

A large insider sale can still be worth monitoring if it coincides with other negative developments, but none are provided here.

Key entities

  • Liquidia Corp

    Company whose insider transaction is disclosed on Form 4.

  • Adair Jason

    Chief Business Officer who executed an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient